Effects of Regular and Long-Acting Insulin on Cognition and Alzheimer's Disease Biomarkers: A Pilot Clinical Trial.

At month 4, the ɛ 4- regular insulin treated participants showed greater improvement than all other groups, an effect that reached significance in comparison with the ɛ 4 + placebo group, and approached significance for the remaining groups (mean change for ɛ 4- regular insulin group = 0.86, SEM = 0.40; for ɛ 4 + placebo = –0.56, SEM = 0.28, p < 0.01; for ɛ 4- placebo mean = –0.08, SEM = 0.39, p = 0.10; for ɛ 4 + regular insulin mean = –0.09, SEM = 0.27, p = 0.06; for ɛ 4- detemir mean = –0.12, SEM = 0.32, p = 0.07; for ɛ 4 + detemir mean = 0.01, SEM = 0.32, p = 0.11).

also in 8,237 other papers